Evidence map›Paper›PMID 42881221›Full record

ArticleNature neuroscience2026

Periventricular gradient pathology is linked to ependymal reactivity and cell adhesion disruption in multiple sclerosis.

Adam M R Groh, Elia Afanasiev, Risavarshni Thevakumaran, Finn Creeggan, Liam Callahan-Martin, Maxime Bigotte, Moein Yaqubi, Joshua Gertsvolf, Junze Pei, Hayden Wu and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Adam M R GrohDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0002-5878-0973
Elia AfanasievDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Risavarshni ThevakumaranDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Finn CreegganDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Liam Callahan-MartinDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Maxime BigotteDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Moein YaqubiDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-7299-5930
Joshua GertsvolfDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Junze PeiDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Hayden WuDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0009-0003-6629-2106
Judith de VosDepartment of Biomedical Engineering and Physics, Faculty of Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0736-7449
Maurice C G AaldersDepartment of Biomedical Engineering and Physics, Faculty of Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Stephanie ZandeeDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0003-0812-676X
Alexandre PratNeuroimmunology Research Laboratory, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-6188-0580
David A RudkoDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Jo Anne StrattonDepartment of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada. jo.stratton@mcgill.ca.ORCID http://orcid.org/0000-0002-1205-1353

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) 486495Multiple Sclerosis Society of Canada (Société Canadienne de la Sclérose en Plaques) 915179
6 · The paper itself

Abstract

Cerebrospinal fluid (CSF)-adjacent brain areas are especially vulnerable to diffuse degeneration in multiple sclerosis (MS). Surface-in gradients arising from CSF-borne cytotoxic factors have been proposed to predict disease relapses independent of white matter lesions. Yet, whether such factors disrupt ependymal cells to penetrate the ventricular border in MS remains unknown. Here, using ultra-high-field magnetic resonance imaging-guided histology, electron microscopy and single-nucleus multiomics, we found that ependymal pathology correlates with periventricular gradients and involves an immune-reactive state marked by transporter and junctional protein dysregulation. We further defined the gene regulatory networks underpinning the MS ependymal state and predicted ligands known to be enriched in MS CSF that could drive the emergence of this state. One of the candidates, IFNγ, increased murine ependymal permeability in vivo, indicating that CSF ligands can modulate ependymal function and regional inflammation. These findings identify CSF-driven ependymal dysfunction as a contributor to periventricular pathology in MS.

Identifiers

PMID42881221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.